India has contributed internationally to randomised Trials on 464 patients for a COVID-19 Vaccine

India has contributed internationally to randomised trial on 464 patients in 39 hospitals in 25 districts across 14 States & Union Territories & have shown that it (plasma therapy) does not reduce mortality or prevent progression from moderate to severe disease.

Advertisement

Coronavirus LIVE updates: India has contributed internationally to randomised trial on 464 patients in 39 hospitals in 25 districts across 14 States & Union Territories & have shown that it (plasma therapy) does not reduce mortality or prevent progression from moderate to severe disease.

3 vaccines at clinical trial stage in India. Cadila and Bharat Biotech have completed phase-I trials. Serum Institute has completed phase II-B3 trials, and will start phase-III trial (with 1,500 patients at 14 locations) after clearances. Plasma therapy has been used for more than 100 years now in some form or the other for various virus infections. It is being used in COVID-19. Whether it helps or not is being studied Prof (Dr) Balram Bhargava, DG, ICMR

“It’s still undergoing peer review. Once peer review happens & we get full publication out, this data will be considered again by National Task Force & joint monitoring group of Health Ministry, then a decision will be taken if we should continue with it” said Balram Bhargava.